Racial and ethnic disparities in disease-modifying therapy use among adults with multiple sclerosis: a real-world analysis of the All of Us Research Program
Victoria Fontánez-Ramos, Jonathan Barreto-Nieves, Grecia A. Carrasquillo-Sanabria, Jorge F. García-Báez, Yaritza Inostroza-Nieves · 2026
Read Racial and ethnic disparities in disease-modifying therapy use among adults with multiple sclerosis: a real-world analysis of the All of Us Research Program by Victoria Fontánez-Ramos, Jonathan Barreto-Nieves, Grecia A. Carrasquillo-Sanabria, Jorge F. García-Báez, Yaritza Inostroza-Nieves (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13616653.txt.
Description
Fontánez-Ramos and co-authors present a 2026 analysis of racial and ethnic gaps in multiple sclerosis drug use. Disease-modifying therapies slow the disease, but access along the care path is uneven. The team used the All of Us research program, a large national data set. Their cohort held 3,508 adults with confirmed disease.
Under half of patients ever started a therapy. Hispanic patients had the lowest start rate, while Black patients started most often but waited longest for a first drug. Use of high-strength drugs varied widely across race and sex groups. Most starters stopped within six months by the study's measure. The authors map gaps at each step of treatment.
Catalog record
| CREATOR | Victoria Fontánez-Ramos, Jonathan Barreto-Nieves, Grecia A. Carrasquillo-Sanabria, Jorge F. García-Báez, Yaritza Inostroza-Nieves |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 39 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |